多瑞吉治疗中晚期癌症疼痛的临床疗效与生活质量分析

The Analysis of Clinic Effects and Quality of Life in the Treatment for Moderate to Sever Cancer Pain

摘要: 目的探讨多瑞吉与美施康定治疗中、重度癌症疼痛的疗效与生活质量。方法将126例中、重度癌症疼痛的患者随机分两组，分别接受多瑞吉（A组）与美施康定（B组）治疗，并记录其疗效、副作用及生存质量。结果多瑞吉与美施康定的疼痛缓解率分别为88．89％、87．30％，疼痛缓解率与生活质量差异均无统计学意义（P〉0．05）。多瑞吉组中的恶心、便秘的副作用发生率则低于美施康定（P〈0．01）。结论多瑞吉是治疗中、重度癌症疼痛的安全、可靠、副作用小的药物。

Abstract: Objective 　To investigate the efficacy, side effects and quality of life between transdermal fentanyl plaster (Durogesic) and sustained release morphine tablet (MS-Contin) in the treatment for moderate to sever cancer pain. Methods 　126 patients were randomized into Durogesic group (group A) and MS-Contin group (group B) . The two groups received Durogesic and MS-contin respectively. Then the efficacy, side effects and quality of life were recorded. Results 　The difference of the effective rates and quality of life of Durogesic and MS-Contin were not significant . However, the incidence of vomit and constipation were significantly higher in the MS-Contin group than that of in the Durogesic group . Conclusion 　The Durogesic is a drug that is safe, reliable and has little side effect in treating moderate to sever cancer pain.